Selected Slide Presentations
Click on the links below to view presentations.

HCV Targets and Replicons

Overview of current HCV targets (Jean-Michel Pawlotsky)

Interferon response against HCV (Christoph Seeger)

Hepatitis C virus-cell entry: a target for anti-viral intervention? (Jane McKeating)

Next Generation of HBV/HCV Inhibitors

Progress with the clinical development of valopicitabine (NM283) in combination with peg-interferon for the treatment of chronic hepatitis C, in treatment-naïve patients and in non-responders to peg-interferon/ribavirin (Christopher O'Brien)

Novel potent inhibitors of the HCV NS3/4 protease (Lawrence Blatt)

Development of a novel mouse model to evaluate drug candidates against wild type and mutant hepatitis B virus (Mark Feitelson)

Therapy for Hepatocellular Carcinoma: Current State and Future Prospects

Current therapies and needs (Eddie Cheung)

Innovative Horizon Lecture

Complex interactions of HBV and its hosts: alterations of human gender ratio (Baruch Blumberg) 

New Therapeutic Approaches and Emerging Targets

The druggable human genome: a long-term view to antiviral agents (Aled Edwards)

The toll road to therapy (Devron Averett)

Regulation of toll-like receptor expression in chronic hepatitis B: role of the precore protein in immunoevasion and pathogenesis (Stephen Locarnini)

Hepatocellular Carcinoma and Fibrosis

Biomarkers for liver fibrosis, steatosis and steatohepatitis (Thierry Poynard)

Resistance to Antiviral Agents

Possible roles of virus replication rates, hepatocyte death rates, trans-complementation and super-infection in the emergence of drug resistant virus strains: theoretical considerations (William Mason)

Hepatitis C virus drug resistance: the impact of in vitro studies on the development of novel antiviral agents targeting viral or host factors (Raffaele De Francesco)

Co-Infection with HIV and Other Viruses

Hepatitis C in the HIV-infected patient (Mark Sulkowski)

HIV HCV co-infection: new therapies (Marion Peters)

Co-infection with HIV/HBV/HCV (Bruce Polsky)

Optimizing Outcome of Therapeutics for Hepatitis Infections: State of the Art Lecture

When to start, when to stop and when to change (Yves Benhamou)

Treatment for HBV

Hepatitis B treatment: 2005 and beyond: an overview (Robert Gish)

Significant and sustained clinical improvement following long term treatment with adefovir dipivoxil: results after 5 years of therapy (Carol Brosgart)

A Phase III comparative trial of telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the large international GLOBE trial (Ching-Lung Lai)

Proof of concept: pradefovir is a liver-targeting antiviral with potent activity against HBV (Zhi Hong)